Upadacitinib Produces Significant Hair Regrowth in Severe Alopecia Areata, Phase 3 Trials Find

A common arthritis medication, upadacitinib, restored substantial hair growth in many people with severe alopecia areata, according to new Phase 3 trial data. The findings offer fresh hope for patients with the autoimmune condition, which can cause sudden and distressing hair loss.

Alopecia areata affects an estimated 2 percent of the global population and often carries a heavy psychological burden. The condition occurs when the immune system mistakenly attacks hair follicles, but the follicles themselves are not permanently destroyed, meaning hair can regrow if the immune attack is halted.

Current treatment options are limited, particularly for adolescents, and responses are often inconsistent. Because upadacitinib targets inflammatory pathways already implicated in alopecia areata, researchers tested whether the drug could restore hair in people with extensive scalp involvement.

How the clinical trials were run

The new research, published in JAMA Dermatology, reports results from two large, parallel Phase 3 randomized clinical trials. Together, they enrolled 1,399 participants aged 12 to 64, including 118 adolescents, all with severe alopecia areata.

Every participant had lost at least half of their scalp hair, scoring 50 or higher on the Severity of Alopecia Tool (SALT), a standard measure used by dermatologists. Over 24 weeks, participants were randomly assigned to take a daily pill containing either 15 milligrams of upadacitinib, 30 milligrams of upadacitinib or a placebo.

The primary goal was to determine how many participants reached a SALT score of 20 or less, meaning at least 80 percent scalp hair coverage by week 24. This threshold is widely used in clinical trials as a marker of meaningful regrowth that patients are likely to notice in everyday life.

Hair regrowth results and response speed

In both trials, upadacitinib clearly outperformed placebo. Among participants taking 15 milligrams, 45.2 percent and 44.6 percent in the two respective trials achieved at least 80 percent scalp coverage. In the 30-milligram groups, the corresponding figures were 55 percent and 54.3 percent.

By comparison, only 1.5 percent and 3.4 percent of participants in the placebo groups reached the same goal. The difference in response emerged early: by week 8, both upadacitinib doses were already separating from placebo in terms of improved SALT scores.

Researchers reported that between 13 percent and 22.5 percent of patients taking upadacitinib, depending on the dose and trial, went on to achieve full scalp hair coverage. This level of regrowth is rare in severe alopecia areata without targeted treatment.

Impact on quality of life and safety

Beyond scalp hair coverage, patients taking upadacitinib showed marked improvements in quality of life and in their own perceptions of change. Many reported better self-esteem and lower emotional distress, important outcomes in a condition closely linked with anxiety and depression.

The short-term safety profile was described as favorable, with serious adverse events occurring in only a small proportion of participants. Common side effects associated with JAK inhibitors such as upadacitinib can include infections, blood clots and changes in blood counts, making long-term safety monitoring essential.

The researchers emphasized that translating visible clinical responses into improvements in patient-reported outcomes is crucial. For people with alopecia areata, the emotional and social consequences of hair loss can be as significant as the physical symptoms.

Limitations, funding and next steps

Despite the promising findings, the trials lasted only 24 weeks, leaving unanswered questions about long-term safety, the durability of hair regrowth and whether ongoing treatment will be necessary. Chronic use of JAK inhibitors has been linked to certain risks that regulators closely monitor.

The two trials were funded and co-designed by AbbVie, the pharmaceutical company that manufactures upadacitinib, and several of the authors are AbbVie employees. While industry sponsorship is common in large dermatology trials, independent research and real-world data will be important for confirming the findings.

Upadacitinib is already approved in several countries for conditions including rheumatoid arthritis, atopic dermatitis and ulcerative colitis. Regulatory authorities may now evaluate the new data as they consider whether to expand its use to include severe alopecia areata.

Experts say further research should directly compare upadacitinib with other approved alopecia areata treatments and explore optimal dosing strategies. For now, the rapid and robust responses observed in these Phase 3 trials suggest the drug could become a significant new option for patients who have long lacked effective therapies.

This article is based on the peer-reviewed trial data and recent clinical literature on alopecia areata and JAK inhibitor therapies.